Boehringer Ingelheim International GmbH

General information

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein, Rhineland-Palatinate
Germany

Contact person: Sebastian Guntrum, Head of Global Legal Human Pharma, Vice President
Company main phone: +49 (6132) 770
Company main fax: +49 (6132) 720
Website: https://www.boehringer-ingelheim.com

Year founded:	1885
Source of foundation:	Independent foundation
Name of foundation source:	Founded by Mr. Albert Boehringer
No. of employees:	Worldwide: 52000

Corporate description / mission:
Boehringer Ingelheim International GmbH researches, develops, manufactures and markets human and veterinary pharmaceutical products. The company's product Aptivus® indicated for combination antiretroviral treatment of HIV-1-infected patients, co-administered with 200 mg of ritonavir, who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.

State of ownership: Private / independent
Headquarters: Yes

Remarks on ownership / listings
Boehringer Ingelheim GmbH was formerly known as Boehringer Ingelheim Zentrale GmbH and changed its name to Boehringer Ingelheim GmbH in 1989.

Categorization

Sector:

Pharma (fully integrated)

Subsector:

Anti-infectives
Antibodies
Nucleic acid drugs
Peptides
Proteins
Vaccines

Primary therapeutic areas:

Cardiovascular / cardiology
Digestive system / gastroenterology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the eye / ophthalmology
Diseases of the nervous system / neurology
Endocrine, nutritional and metabolic diseases / endocrinology
External causes of morbidity and mortality / traumatology
Genitourinary system / Urology
Infectious and parasitic diseases / infectiology / parasitology
Mental and behavioural disorders / psychiatry /psychology
Neoplasms / cancer / oncology
Respiratory / pulmonology
Skin and subcutaneous tissue / dermatology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

Manufacturer
R&D
Supplier / Distributor

Customer segments:

Hospitals
Large biotech & big pharma
Physicians / doctors
Small biotech

Distribution:

Direct (own sales force)
Indirect (independent dealer)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	4
Phase I:	31
Phase II:	17
Phase III:	10
On the market:	9

Description of products:
Jardiance (Empagliflozin)
Spesolimab (BI 655130)
BI 685509, etc.

Collaborations & Clients

Partnering strategy / collaborations:
Institute of Molecular Pathology (IMP)
Institute of Molecular Biology (IMB)
University of Applied Sciences in Biberach, Germany
University of Ulm, Germany
Technische Universität Dresden, etc.